News

Patients receiving high-dose therapy for mantle cell lymphoma are at a higher risk of treatment failure if they have mutations in the TP53 or KMT2D genes, according to new research.

MET amplifications are found in up to 10% of patients with EGFR-mutant NSCLC who progress on first- or second-generation EGFR TKIs and in up to 25% of those who progress on a third-generation EGFR TKIs, necessitating the need for treatment options in the population.

With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,

"As the first FDA-approved therapy to treat this debilitating disease, today’s action is an important step in finding treatment options for patients living with tumor-induced osteomalacia whose tumor cannot be found or removed."

"When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTK C481S mutation, while it did not show superior activity than the first-in-class BTK [inhibitor] in in vitro and in vivo models of ibrutinib-resistant MCL with constitutive activation of the non-canonical NF-KB pathway.”

"The iNNOVATE study continues to deliver strong clinical evidence supporting the long-term use of ibrutinib plus rituximab across first and second lines of therapy for patients with Waldenström's macroglobulinemia."

In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed how CAR T-cell therapy could play a role in the treatment of solid tumors. He highlighted the current research and next steps planned to move this cellular therapy into the solid tumor treatment landscape.

These data suggest that screening for pulmonary hypertension is warranted in patients with a Philadelphia chromosome-negative myeloproliferative neoplasm, both at the time of diagnosis and during follow-up.

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.

The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."

“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."

“The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”

“RASMT associated with adverse phenotypic features were concluded to be an independent predictor of inferior overall survival and were associated with a higher cumulative incidence of leukemic transformation."

Targeted Oncology reviews trending news online for the week of June 19, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

“Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result."

During a debate made available as part of the 2020 National Comprehensive Cancer Network Virtual Annual Conference, Deborah Stephens, DO, and Mazyar Shadman, MD, MPH, discussed the most optimal frontline therapy for chronic lymphocytic leukemia.

IMpassion031, a clinical trial of atezolizumab plus chemotherapy in patients with triple-negative breast cancer, has met its primary end point.

In an interview with  Targeted Oncology,  Marcia Brose, MD, PhD, discussed the importance of conducting genetic testing on all patients with metastatic solid tumors following the exciting data on larotrectinib.

Fruquitinib was granted Fast Track Designation for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, as well as anti-EGFR therapy for RAS wild-type tumors

“Community-based clinical trials come with many benefits. They enable patients to be matched with potentially life-saving research while staying within the comfort and familiarity of their local oncologist’s office.”

"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."

FoundationOne CDx has been approved by the FDA as a companion diagnostic for pembrolizumab to identify patients with tumor mutational burden–high solid tumors who would benefit from this therapy.

“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."

In an interview with Targeted Oncology, Suresh Ramalingam, MD, FASCO, discussed the findings from the CheckMate 227 study that support the FDA’s approval of the combination of nivolumab and ipilimumab in patients with advanced NSCLC.

A liposomal irinotecan combination was granted FDA Fast Track designation for the treatment of untreated and unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.

“While the trial is still ongoing, we are encouraged by the efficacy we are seeing thus far in patients with relapsed/refractory AML, particularly the durability of response observed in some patients."

"KEYNOTE-158 has confirmed clinical activity of pembrolizumab in tumors harboring a TMB ≥10 across a variety of solid tumors including anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small cell lung, thyroid, and vulvar cancers."